mTOR

Torin 1 is a potent ATP-competitive mammalian target of rapamycin (mTOR) inhibitor with an IC 50 value of 3nM.

INK 128 (MLN0128) (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.

AZD2014 (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity.

ATR inhibitor,potent and selective

PI3K and mTOR inhibitor, brain-permeable

dual PI3K/mTOR inhibitor

MTOR inhibitor,potent,ATP-competitive and cell-permeable

Dual inhibitor of tyrosine and phosphoinositide kinases

PI3K and mTOR inhibitor,potent and reversible

PI-103 is a potent cell-permeable multi-target inhibitor that primarily acts on the PI3K and mTOR signaling pathways.

third-generation mTOR inhibitor

MTOR inhibitor

An inhibitor of cell proliferation

Temsirolimus (CCI-779), an ester of rapamycin, inhibits the activity of mTOR kinase activity with an IC 50 value of 1.76 ± 0.15μM.

PI3K/Akt/mTOR inhibitor

Everolimus (RAD001) is an orally effective second-generation mTOR inhibitor.

CC-223 (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. CC-223 inhibits both mTORC1 and mTORC2.

MHY1485 is a cell-permeable mTOR activator.

Dual DNA-PK/PI3-K inhibitor, ATP-competitive

LY3023414 (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations.